Skip to main content

Here are the top reads on deals and financial services over the last 24 hours,

FINANCIAL SERVICES NEWS

Canada’s big banks are fighting to win doctors’ trust – and their money: Just days after Bank of Nova Scotia unveiled its hefty $2.6-billion bid to buy MD Financial Management last May, Leo Salom called together what he calls his “SWAT team.” Story (Clare O’Hara)

Story continues below advertisement

Return of the REITs: Financing rush makes real estate the hottest sector on Bay Street: Canadian real estate investment trusts are capitalizing on a growing hunger for yield-driven stocks, tapping investors for fresh cash in an unexpected flurry of financings. Story (Tim Kiladze)

Sidewalk Labs courting local venture capitalists to back smart-city project on Toronto waterfront: Google affiliate Sidewalk Labs has been trying to win the support of Canada’s venture-capital community in the months leading up to a crucial make-or-break deadline for its proposal to develop a high-tech neighbourhood on Toronto’s waterfront. Story (Josh O’Kane)

DEALS NEWS: MERGERS, ACQUISITIONS, IPOs and FINANCINGS

Hudson’s Bay agrees to be taken private after Baker group hikes bid: A group led by Hudson’s Bay Co. executive chairman Richard Baker raised its takeover offer for the department store chain by $100-million on Monday and won approval for the bid from members of the company’s board of directors. Story (Andrew Willis and Rachelle Younglai)

Why Baker’s offer for HBC is unlikely to go higher: The numbers behind Richard Baker’s sweetened privatization offer for Hudson’s Bay Co. are a testament to the dire state of department-store retail. They also show why an even richer bid from his group of insiders is unlikely. Opinion (Jeffrey Jones)

Pension funds pay double last year’s IPO price for AltaGas Canada: Two Canadian pension funds are teaming up to acquire AltaGas Canada Inc., paying more than double the company’s initial public offering price only one year ago. Story (Tim Kiladze)

Knight Therapeutics buys Latin American drug company for $400-million: Jonathan Goodman has finally gone shopping. Knight Therapeutics Inc., the pharmaceutical company Mr. Goodman founded and leads as chief executive, announced Monday it will buy Latin American oncology drug specialist Grupo Biotoscana Investments in a deal worth $369-million. It is Knight’s first major acquisition and puts to work the bulk of a cash pile that topped $600-million at the end of June. Story (Nicolas Van Praet)

Story continues below advertisement

Montreal’s Lightspeed to pay up to US$61-million for Kounta Holdings in biggest acquisition yet: Montreal-based Lightspeed POS Inc. has announced its third acquisition since going public seven months ago and the largest in its 14-year history. Story (Sean Silcoff)

The Streetwise newsletter is Monday to Friday. If you’re reading this on the web, or if someone forwarded this e-mail to you, you can sign up for Streetwise and all Globe newsletters on our signup page.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter